Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Sihuan Pharmaceutical and dProtein Biotechnology Form AI-Powered Medical Aesthetics Joint Venture

Fineline Cube May 29, 2026
Company Deals Drug

Salvectors Receives NMPA Clinical Approval for YB1-X7, World’s First Oncolytic Salmonella Therapy for Advanced Solid Tumors

Fineline Cube May 29, 2026
Company Deals

Kexing Pharmaceutical and Sinotherapeutics Partner to Commercialize Tofacitinib Extended-Release Tablets in Kuwait and Mexico

Fineline Cube May 29, 2026
Company Deals

Genrix Bio Licenses BCMA×CD3 Bispecific Velinotamig to Fosun’s Yaopharma for Greater China in $268M Deal

Fineline Cube May 29, 2026
Company Deals

Innovent Biologics and Pfizer Forge $10.5B Global Oncology Partnership Spanning 12 First-in-Class Programs

Fineline Cube May 29, 2026
Policy / Regulatory

China’s NHSA Proposes First National Basic Medical Insurance Medical Service Items List to Standardize Reimbursement Framework

Fineline Cube May 29, 2026
Company Drug

Sanofi’s Venglustat Receives FDA Priority Review and Breakthrough Therapy Designation for Type 3 Gaucher Disease

Fineline Cube May 29, 2026
Company Drug

BeOne Medicines and Amgen’s Tarlatamab Receives NMPA Conditional Approval for Second-Line ES-SCLC in China

Fineline Cube May 29, 2026
Company Deals

VIVA Biotech Secures Licensing Deal with Lonza for Advanced Bispecific Antibody Technology

Fineline Cube Mar 21, 2024

VIVA Biotech Holdings (HKG: 1873), a China-based Contract Research Organization (CRO), has entered into a...

Company Drug

Antengene’s ATG-022 Advances to Dose Expansion Phase in Phase II CLINCH Study for Solid Tumors

Fineline Cube Mar 21, 2024

Antengene Corporation Ltd (HKG: 6996), a leading biopharmaceutical company based in China, has announced that...

Company Drug

CSPC Pharmaceutical Secures NMPA Approval for Clinical Study of SYS6023 in Advanced Solid Tumors

Fineline Cube Mar 21, 2024

CSPC Pharmaceutical Group Ltd (HKG: 1093), a prominent China-based biopharmaceutical company, has received approval from...

Company

3SBio Reports 13.8% Revenue Growth in 2023, Driven by Strong Sales of Core Biologics

Fineline Cube Mar 21, 2024

3SBio Inc. (HKG: 1530), a leading China-based biopharmaceutical company, has reported its 2023 financial results,...

Company

Innovent Biologics Reports 36.2% Revenue Growth in 2023, Highlights Robust Product Sales

Fineline Cube Mar 21, 2024

Innovent Biologics Inc. (HKG: 1801), a China-based biotechnology firm, has released its 2023 financial report,...

Company Drug

Jiangsu Hengrui Receives NMPA Approval for Phase Ib/II Study of HRS2398 in Advanced Solid Tumors

Fineline Cube Mar 20, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...

Company Deals

Zuellig Pharma Expands Commercialization Deal for Karo Healthcare’s Lamisil in Asian Markets

Fineline Cube Mar 20, 2024

Zuellig Pharma, a Singapore-based healthcare solutions provider, has announced the expansion of its commercialization agreement...

Company Drug

CSPC Pharmaceutical Gets NMPA Greenlight for SYH2039 Clinical Study in Advanced Malignant Tumors

Fineline Cube Mar 20, 2024

CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has received...

Company

Novo Nordisk Invests RMB 4 Billion to Expand Sterile Manufacturing in Tianjin

Fineline Cube Mar 20, 2024

Novo Nordisk (NYSE: NVO), a Denmark-based leader in diabetes care, has announced a substantial investment...

Company Deals

Suzhou Porton Biologics Partners with Kunshi Biotech to Advance Third-Generation CAR-M Therapy

Fineline Cube Mar 20, 2024

Suzhou Porton Biologics Ltd, a China-based Contract Development and Manufacturing Organization (CDMO), has entered into...

Policy / Regulatory

China Expands Medical Service Pricing Reform with Three Additional Pilot Provinces

Fineline Cube Mar 20, 2024

The National Healthcare Security Administration (NHSA) has announced an expansion of its medical services pricing...

Company

Swiss Pharma Firm Carbogen Amcis Receives Brazil’s ANVISA GMP Certification for Shanghai Site

Fineline Cube Mar 20, 2024

Carbogen Amcis, a Swiss firm specializing in active pharmaceutical ingredients (APIs) and pharmaceutical process development,...

Company

Everest Medicines Strengthens Leadership with Appointments of Sandra Zeng and Rico Liang

Fineline Cube Mar 20, 2024

Everest Medicines (HKG: 1952), a leading China-based biotechnology company, has announced two significant appointments to...

Company

WuXi XDC Breaks Ground on State-of-the-Art Manufacturing Base in Singapore to Boost ADC Production

Fineline Cube Mar 20, 2024

WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...

Company Deals

Shanghai Winpu Technology and Silver Mars Merge Under YinKe Holding to Accelerate Healthcare Innovation

Fineline Cube Mar 20, 2024

Shanghai Winpu Technology Co., Ltd., a specialist in medical-grade polymer materials based in China, has...

Company Drug

Everest Medicines’ Nefegan Approved by Singapore HSA for Primary IgAN Treatment

Fineline Cube Mar 20, 2024

Everest Medicines (HKG: 1952), a China-based biotechnology company, has received marketing approval from the Singapore...

Company

Shanghai Pharmaceuticals Appoints New Chairman Amid Leadership Shake-up

Fineline Cube Mar 20, 2024

Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607), one of the leading pharmaceutical giants in China,...

Company Deals

AstraZeneca to Acquire Fusion Pharmaceuticals in a Deal Valued at USD 2.4 Billion

Fineline Cube Mar 20, 2024

AstraZeneca (AZ; NASDAQ: AZN), the UK-based pharmaceutical giant, has announced its intention to acquire Fusion...

Company

China Grand Pharmaceutical Reports Robust 2023 Revenues and Pipeline Advancements

Fineline Cube Mar 20, 2024

China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has reported its financial results...

Company Drug

Dr. Reddy’s Launches Biosimilar Versavo in UK to Challenge Roche’s Cancer Therapy Avastin

Fineline Cube Mar 20, 2024

Dr. Reddy’s Laboratories (NYSE: RDY), a prominent Indian pharmaceutical company, has launched its biosimilar Versavo...

Posts pagination

1 … 395 396 397 … 674

Recent updates

  • Sanofi’s Venglustat Receives FDA Priority Review and Breakthrough Therapy Designation for Type 3 Gaucher Disease
  • BeOne Medicines and Amgen’s Tarlatamab Receives NMPA Conditional Approval for Second-Line ES-SCLC in China
  • Northland Biotech’s Engensis Gene Therapy Receives NMPA Approval for Severe Lower Limb Ischemia Ulcers
  • AstraZeneca’s Fasenra Becomes First Biologic Approved in China for Hypereosinophilic Syndrome
  • Shionogi’s Symproic (Naldemedine) Receives NMPA Approval for Opioid-Induced Constipation in China
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Sanofi’s Venglustat Receives FDA Priority Review and Breakthrough Therapy Designation for Type 3 Gaucher Disease

Company Drug

BeOne Medicines and Amgen’s Tarlatamab Receives NMPA Conditional Approval for Second-Line ES-SCLC in China

Company Drug

Northland Biotech’s Engensis Gene Therapy Receives NMPA Approval for Severe Lower Limb Ischemia Ulcers

Company Drug

AstraZeneca’s Fasenra Becomes First Biologic Approved in China for Hypereosinophilic Syndrome

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.